display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positive
la/mBC - HER2 positive - 1st Line (L1)
HER2 inhibitor
pertuzumab based treatment
pertuzumab plus trastuzumab PERTAIN
pertuzumab plus trastuzumab plus docetaxel CLEOPATRA PUFFIN
trastuzumab based treatment
trastuzumab plus endocrine therapy SYSUCC-002

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons